Pharmaceuticals firm Indoco Remedies announced Q3FY24 results: Q3FY24 Revenue: Rs 4,484 million (growth of 9.2% compared to Rs 4,106 million in Q3 of the previous year) EBIDTA: Rs 653 million, representing 14.6% of net sales (compared to Rs 617 million or 15.0% of net sales in Q3 of the previous year) Profit After Tax: Rs 282 million (before exceptional item), which is comparable to the profit of Rs 279 million reported in the same quarter last year 9MFY24 (Apr-Dec) Revenue: Rs 13,268 million (9.6% increase from Rs 12,101 million in the same period last year) EBIDTA: Rs 2,006 million, 15.1% of net sales (against Rs 2,207 million, 18.2% of net sales in the previous year) Profit After Tax: Rs 873 million (before exceptional item), 6.6% of net sales (compared to 9.6% or Rs 1,160 million in the same period last year) Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated: "Our Q3 performance is primarily driven by International business particularly US and Emerging Markets, API business and steady performance by India business." Result PDF
Pharmaceuticals company Indoco Remedies announced Q1FY24 results: Revenues of Indoco Remedies grew by 5% at Rs 413.2 crore, as against Rs 394.9 crore in Q1FY23. EBIDTA to net sales for Q1FY24 is 15.2% at Rs 62.9 crore, compared to 18.1 % at Rs71.3 crore in Q1FY23. Profit After Tax is at Rs 25.7 crore, compared to Rs 37.5 crore in Q1FY23. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our first quarter results demonstrate good growth in API business, complemented by steady performance in the Domestic Formulation business. We remain optimistic for the rest of the year and are committed to building and further strengthening our position in the market”. Result PDF